| Literature DB >> 28817701 |
Sarah R Chang1,2, Rudi Kobetic1, Ronald J Triolo1,2,3.
Abstract
An important consideration in the design of a practical system to restore walking in individuals with spinal cord injury is to minimize metabolic energy demand on the user. In this study, the effects of exoskeletal constraints on metabolic energy expenditure were evaluated in able-bodied volunteers to gain insight into the demands of walking with a hybrid neuroprosthesis after paralysis. The exoskeleton had a hydraulic mechanism to reciprocally couple hip flexion and extension, unlocked hydraulic stance controlled knee mechanisms, and ankles fixed at neutral by ankle-foot orthoses. These mechanisms added passive resistance to the hip (15 Nm) and knee (6 Nm) joints while the exoskeleton constrained joint motion to the sagittal plane. The average oxygen consumption when walking with the exoskeleton was 22.5 ± 3.4 ml O2/min/kg as compared to 11.7 ± 2.0 ml O2/min/kg when walking without the exoskeleton at a comparable speed. The heart rate and physiological cost index with the exoskeleton were at least 30% and 4.3 times higher, respectively, than walking without it. The maximum average speed achieved with the exoskeleton was 1.2 ± 0.2 m/s, at a cadence of 104 ± 11 steps/min, and step length of 70 ± 7 cm. Average peak hip joint angles (25 ± 7°) were within normal range, while average peak knee joint angles (40 ± 8°) were less than normal. Both hip and knee angular velocities were reduced with the exoskeleton as compared to normal. While the walking speed achieved with the exoskeleton could be sufficient for community ambulation, metabolic energy expenditure was significantly increased and unsustainable for such activities. This suggests that passive resistance, constraining leg motion to the sagittal plane, reciprocally coupling the hip joints, and weight of exoskeleton place considerable limitations on the utility of the device and need to be minimized in future designs of practical hybrid neuroprostheses for walking after paraplegia.Entities:
Mesh:
Year: 2017 PMID: 28817701 PMCID: PMC5560635 DOI: 10.1371/journal.pone.0183125
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subject characteristics.
| Subject | Gender | Age | Weight (kg) | Height (cm) |
|---|---|---|---|---|
| 1 | F | 27 | 62 | 165 |
| 2 | M | 66 | 73 | 180 |
| 3 | M | 23 | 67 | 170 |
| 4 | M | 58 | 74 | 173 |
| 5 | M | 53 | 68 | 167 |
| 6 | F | 45 | 57 | 164 |
Fig 1Subject wearing exoskeleton and metabolic analyzer.
Average walking speed, cadence, and step length for each subject walking with and without the exoskeleton.
| Subject | Speed | Cadence | Step Length | |||
|---|---|---|---|---|---|---|
| With Exo | Without | With Exo | Without | With Exo | Without | |
| 1 | 0.9 ± 0.1 | 1.3 ± 0.4 | 86 ± 4 | 106 ± 50 | 66 ± 5 | 77 ± 10 |
| 2 | 1.4 ± 0.1 | 1.4 ± 0.4 | 103 ± 5 | 112 ± 47 | 80 ± 1 | 79 ± 11 |
| 3 | 1.2 ± 0.1 | 1.3 ± 0.2 | 97 ± 5 | 107 ± 12 | 71 ± 2 | 70 ± 3 |
| 4 | 1.2 ± 0.1 | 1.2 ± 0.1 | 105 ± 2 | 102 ± 5 | 68 ± 8 | 72 ± 3 |
| 5 | 1.2 ± 0.1 | 1.2 ± 0.03 | 117 ± 4 | 105 ± 1 | 63 ± 5 | 68 ± 2 |
| 6 | 1.4 ± 0.1 | 1.4 ± 0.1 | 113 ± 4 | 116 ± 5 | 73 ± 2 | 71 ± 2 |
Fig 2O2 consumption for each subject and averaged across all subjects when walking with and without the exoskeleton.
Fig 3Percent of age corrected maximum heart rate for each subject and averaged across all subjects when walking with and without the exoskeleton.
Speed, METs, and PCI for different conditions and devices.
| Device | User | Speed [m/s] | METs | PCI [beats/m] |
|---|---|---|---|---|
| Exoskeleton | able-bodied | 1.2 ± 0.2 | 6.5 ± 1.0 | 1.1 (range: 0.74 to 1.28) |
| Bilateral knee-ankle-foot orthoses [ | SCI (paraplegia, n = 3) | 0.28 ± 0.22 | 4.6 ± 0.7 | -- |
| FNS [ | SCI (T4-T12) | 0.2–0.4 (n = 5) | -- | 2.3–6.3 (n = 4) |
| RGO+FNS [ | SCI (T4, n = 1) | 0.42 | -- | 1.54 |
| Powered exoskeletons [ | SCI (C4-L1, n = 116) [ | 0.27 (95% CI: 0.22–0.33) [ | 3.3 (95% CI: 2.2–4.4) [ | -- |
(95% CI = 95% confidence interval, C = cervical, L = lumbar, n = sample size, T = thoracic)